NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted FCF Margin of 1007.96% for Q1 2026, up 99.21% sequentially from 128046.88% in Q4 2025, and up 21716.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported FCF Margin for 4 years, with the latest figure at 1007.96% in Q1 2026.
- Quarterly FCF Margin rose 21716.0% year-over-year to 1007.96% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 630.12% (down 33158.0% YoY) and the FY2025 annual result came in at 657.82%, down 30833.0% from the prior year.
- FCF Margin improved to 1007.96% in Q1 2026 per NAMS's latest filing, from 128046.88% in the prior quarter.
- Over five years, FCF Margin peaked at 43.2% in Q3 2024 and troughed at 128046.88% in Q4 2025.
- A 4-year average of 12719.25% and a median of 1411.35% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin soared 382569 bps in 2024, then plunged 12775339 bps in 2025.
- Over 4 years, FCF Margin stood at 4119.18% in 2023, then surged by 93 bps to 293.49% in 2024, then slumped by 43530 bps to 128046.88% in 2025, then surged by 99 bps to 1007.96% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1007.96%, 128046.88%, and 9428.45% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | -1,061.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,061.71% |
| Mar 31, 2026 | -1,007.96% |
| Dec 31, 2025 | -128,046.88% |
| Sep 30, 2025 | -9,428.45% |
| Jun 30, 2025 | -197.23% |
| Mar 31, 2025 | -1,225.12% |
| Dec 31, 2024 | -293.49% |
| Sep 30, 2024 | -43.20% |
| Jun 30, 2024 | -2,377.71% |
| Mar 31, 2024 | -3,924.84% |
| Dec 31, 2023 | -4,119.18% |
| Sep 30, 2023 | -1,597.59% |
| Jun 30, 2023 | -1,707.05% |
| Mar 31, 2023 | -369.34% |